If you are in an emergency, in crisis or need someone to talk to, there is help.

View Crisis Resouces
Skip to content
  • Contact Us
  • No One Left Behind
  • Join our team
  • Vaccine Clinic
  • Accessibility
CAMH logo
  • Your Care
    • Main Page
    • Access CAMH & Referral Form
      • Access CAMH

        Centralized information, intake and scheduling. Access CAMH makes it easy to find support – simply call 416-535-8501, option 2.

      • Referral Form

        For mental health services, a referral form needs to be completed by a healthcare provider. For addictions services, patient can self-refer.

    • Programs & Services
      • Addictions/Substance Use
      • Aggression & Behavioural Issues
      • Alzheimer’s & Dementia
      • Anxiety & Depression
      • Concurrent Disorders
      • Developmental Disabilities
      • Mood & Personality Disorders
      • Problem Gambling
      • Schizophrenia & Psychosis
      • Trauma & Stress Disorders
      • Virtual Mental Health and Outreach
      • Other
    • Patient Wellness
    • Planning Your Care
      • Supporting Families

        Family members play an essential role the recovery of a loved one. The Office of Family Engagement is here for you.

      • Staying at CAMH

        Be prepared with all the info you need to make your inpatient experience at CAMH as comfortable as possible.

    • Your Rights
      • Client Relations
      • Bill of Client Rights
      • Empowerment Council
      • Legal Rights, Protection of Health Info & Access to Records
    • Visiting CAMH
      • Visiting CAMH

        Planning on visiting CAMH? Find contact information, directions and accessibility for each of our three main sites.

        Read More
  • Health Info
    • Main Page
    • Mental Illness & Addiction Index
      • Conditions & Disorders
      • Medication Therapies
      • Substance Use
      • Types of Treatment
      • Information in Other Languages
    • Mental Health 101
      • Mental Health 101

        Use this series of free online tutorials as the starting point to learn about and understand a wide range of mental health topics.

        Read More
    • Guides & Publications
      • Guides & Publications

        Accessible, reliable, professionally produced resources on an array of mental health topics for patients, families, students and professionals.

        Read More
    • Crisis Resources
      • Crisis Resources

        If you are in an emergency, in crisis or need someone to talk to, there is a list of resources available for areas in and around Toronto.

        Read More
    • CAMH Store
      • CAMH Store

        The CAMH Store offers a wide array of mental illness and addiction resources for patients, families, students and professionals. Search or browse our catalogue of brochures and booklets, textbooks, manuals and assessment tools.

        Read More
    • CAMH Library
      • CAMH Library

        Open to professionals and the general public, our comprehensive resources and services support and enhance CAMH's research and clinical programs, and they facilitate learning, dynamic knowledge exchange and health promotion initiatives.

        Read More
    • Workplace Mental Health Playbook
    • Mental Health and the COVID-19 Pandemic
      • Coping with stress & anxiety
      • Quarantine & isolation
      • Stigma and prejudice
      • Loss, grief and healing
      • Resources for Health Care Workers
  • Research
    • Main Page
    • Research Areas at CAMH
      • Brain Science

        CAMH is revolutionizing our understanding of the brain and the causes, biomarkers and treatments of mental illness.

      • Personalized Care

        By understanding diverse groups, we prevent, diagnose and care for each one with greater precision and personalization.

      • Prevention and Policy

        Using evidence, we drive system and social change to optimize care and reduce the burden of mental illness, including addictions, across populations.

    • The Discovery Fund
      • The Discovery Fund

        Fuelling the next generation of groundbreaking research and innovation dedicated to finding the causes of and cures for mental illness.

        Read More
    • Institutes & Centres
      • Azrieli Adult Neurodevelopmental Centre
      • Azrieli Centre for Neuro-Radiochemistry
      • Brain Health Imaging Centre
      • Campbell Family Mental Health Research Institute
      • Centre for Youth Bipolar Disorder
      • Cundill Centre for Child and Youth Depression
      • Institute for Mental Health Policy Research
      • Krembil Centre for Neuroinformatics
      • Slaight Family Centre for Youth in Transition
      • Tanenbaum Centre for Pharmacogenetics
      • Temerty Centre for Therapeutic Brain Intervention
      • The Margaret and Wallace McCain Centre for Child Youth & Family Mental Health
    • Clinical Divisions
      • Addictions Division
      • Adult Neurodevelopmental and Geriatric Psychiatry Division
      • Child and Youth Psychiatry Division
      • Forensic Psychiatry Division
      • General and Health Systems Psychiatry Division
      • Psychology Division
      • Schizophrenia Division
    • Research Discoveries
      • Research Discoveries

        At the leading edge of breakthrough mental health and addiction research for over 50 years.

      • BrainBuzz Newsletter

        The latest news, groundbreaking discoveries and special features about CAMH research, studies, and the people behind the work.

      • Research Strategic Plan

        Learn what drives our research agenda and priorities in the CAMH Research Plan for 2018-2023

    • Research Connect
      • Research Connect FAQs
      • Research Ethics
    • Research Students & Fellows
      • Research Students & Fellows

        Train in a unique and welcoming learning environment with Canada's leading scientists in mental illness and addiction.

        Read More
    • Science & Research Staff Directory
      • Our Scientific Staff
      • Research Chairs at CAMH
    • Tech Transfer & Industry Partnerships
  • Education
    • Main Page
    • Continuing Education Programs and Courses
      • Find the Course That's Right for You

        Browse our entire selection of certificate programs, webinars and workshops.

      • Workplace Education and Consulting

        View our full list of workplace mental health workshops and consulting services

    • Collaborative Learning College
    • Simulation Centre
    • Student Centre
    • Clinical & Research Opportunities for Professionals in Training
      • Clinical Psychology Training Programs
      • Community-Based Research Fellowship
      • Graduate & Post-Doctoral Fellowships in Public Health Policy
      • Clinical & Research Opportunities for Professionals in Training

        Study in a world-class setting to become a leader in the field of mental health.

    • Academic & Education Research Excellence
      • Academic & Education Research Excellence

        Inspired teaching fosters inspired learning – CAMH improves the quality of care for all through excellence in professional education.

        Read More
    • CAMH Business Development Office Contacts
    • CAMH Education Contacts
  • Professionals _
    • Main Page
    • Treating Conditions and Disorders
      • Adult ADHD
      • Anxiety Disorders
      • Canadian Opioid Use Disorder Guideline
      • Dementia
      • Depression
      • Disability & insurance claims in primary care
      • Eating Disorders
      • Fundamentals of Addiction
      • Intellectual & Developmental Disabilities
      • Mania
      • OCD
      • Perinatal Mood & Anxiety Disorders
      • Personality Disorders
      • Psychosis
      • Posttraumatic Stress Disorder
      • Sleep Disorders
      • Smoking Cessation
      • Suicide Risk
      • Psychiatric Interviewing
      • The CARIBOU Pathway by CAMH
    • Professionals Projects
      • Immigrant and Refugee Mental Health Project
      • Opioid Use in Primary Care Conference 2023
    • Videos
    • Podcasts
  • Get Involved
    • Main Page
    • Ways to Donate
      • Give Monthly
      • Give In Memory or In Honour
      • Explore the Giving Hub
      • Start a Fundraiser
      • Gifts of Celebration
      • Leave a Gift in Your Will
      • Employee Matching & Payroll Deduction
      • Donate Goods & Services
      • Gifts of Securities
      • Canvassers & Callers
      • Make a one-time donation

        With your support, CAMH researchers are revolutionizing the ways we diagnose, treat, and prevent mental illness. Donate today.

    • Join the Cause
      • Business Leaders for Mental Health Action
      • Visionary Society
      • Michael Wilson Society
      • CAMH Engage
      • Corporate Partnerships
      • Volunteer at CAMH
    • Putting Your Donations to Work
      • Putting Your Donations to Work

        Every donation you make to CAMH enables us to directly help Canadians living with mental illness— and countless more worldwide—through the discoveries we share.

        Read More
    • Making a Real Impact
      • Making a Real Impact

        Real stories of courage, hope and discovery. Made possible through your continued support of CAMH.

        Read More
  • Driving Change
    • Main Page
    • About CAMH
      • Leadership Team Directory
      • Performance & Accountability
      • The Role of CAMH Foundation
      • For Reporters
      • Events Calendar
      • For Our Neighbours
      • Contact CAMH
      • One CAMH: Strategic Plan 2020-2023
      • Careers at CAMH

        Interested in working at CAMH and making a difference? Put your skills and passion to work in a dynamic, supportive environment—and help transform lives and the future of mental health care.

    • The Crisis is Real
      • The Crisis is Real

        We are in the grips of a crisis that ruins health, threatens lives and hurts economies. Knowing the facts is the first step in creating hope.

      • Mental Health Statistics

        The latest facts and statistics on mental illness and addiction, who's affected and their impact on Canadians.

    • Addressing Stigma
      • Addressing Stigma

        Challenging the stigma associated with mental illness takes understanding, education and a closer look at our own attitudes toward health.

        Read More
    • The Mental Health Facility of the Future
      • The Mental Health Facility of the Future

        Turning what was once a walled institution into a symbol of hope for the future of mental health care.

      • Vision & Guiding Principles

        How do you replace an institution with an urban village? Lots of planning, imagination and a long-term commitment to serving patients, staff and the community.

      • History of Queen Street Site

        Our history—evolving from an asylum into a modern health facility with patients at the centre of care—is the history of mental health care in Canada.

    • Provincial System Support Program
      • Provincial System Support Program

        CAMH’s Provincial System Support Program collaborates to support the province’s Mental Health and Addictions Strategy and make sustainable, system-level change.

        Read More
    • Influencing Public Policy
      • Influencing Public Policy

        CAMH advocates for policies that are responsive to the needs of people with mental illness and addictions.

        Read More
    • Health Equity
      • Health Equity

        CAMH believes in the principle of equity. We respect the diversity of the individuals and communities we serve.

        Read More
    • Game Changers
    • Shkaabe Makwa
    • CAMH News & Stories
    • Contact Us
    • No One Left Behind
    • Join our team
    • Vaccine Clinic
    • Accessibility

Depression: Psychopharmacology

CAMH Logo
  • Depression: Psychopharmacology
Back to top
  • Home
  • Professionals
  • Treating Conditions and Disorders
  • Depression
  • Treatment
  • Psychopharmacology
CAMH logo
  • Depression
  • Screening & Assessment
  • Diagnosis
  • Treatment
  • Clinical tools
Back to top

Text adapted from "The patient who is depressed" in Psychiatry in primary care by Raymond W. Lam,  (CAMH, 2019).


Acute Treatment


The goals for acute treatment of depression are full symptom remission and return to baseline functioning. Among patients undergoing primary care treatment for depression, 60 to 80 per cent achieve symptom remission. Remission typically is defined as having normal mood and minimal symptoms, but it is best evaluated using a rating scale (e.g., a score within the normal range on the PHQ-9 , Hamilton Depression Rating Scale or Beck Depression Inventory ).


Antidepressant medications are the first-choice treatment for moderate to severe depression. (For treatment of mild to moderate depression, see “Psychotherapy.”) The newer antidepressants—selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine and vortioxetine—are all first- line medications, offering improved tolerability and a better safety profile compared with tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) (Bezchlibnyk-Butler et al., 2014; Stahl, 2017). The following tables summarize antidepressant characteristics.

Related

  • Psychiatry in Primary Care: A Concise Canadian Pocket Guide 2019

    Read More

  • Depression: Health Information for your Patient

    Read More

  • Depression: An Information Guide

    Read More

Table 1: First-Line Antidepressant Medications, Doses and Profiles

Medication (Brand Name)Usual Daily Dose (mg)EfficacyaTolerabilitybAnxietyc
SSRI    
Citalopram (Celexa)20-40 ✓ 
Escitalopram (Cipralex)10-20✓✓✓
Fluoxetine (Prozac)20-40   
Fluvoxamine (Luvox)100-200   
Paroxetine (Paxil)20-40  ✓
Sertraline (Zoloft)50-150✓✓✓
SNRI    
Desvenlafaxine (Pristiq)50-100 ✓✓
Duloxetine (Cymbalta)60-120  ✓
Venlafaxine-XR (Effexor)75-225✓✓
Other medication    
Buproprion-SR (Wellbutrin)150-300✓ 
Mirtazapine (Remeron)30-60✓  
Trazodone (Desyrel)200-400   
Vortioxetine (Trintellix)5-20   

  1. Evidence for superior efficacy is based on meta-analyses (Kennedy et al., 2016).
  2. Evidence for better tolerability is based on meta-analyses (Cipriani et al., 2009).
  3. Evidence for efficacy in anxiety disorders is based on Canadian guidelines (Katzman et al., 2014).

Table 2: Second-and-Third-Line Antidepressants Medications and Doses

Medication (Brand Name) Drug Class Usual Daily Dose
Second-line antidpressant a    

Levomilnacipran (Fetzima) b



SNRI



 40-120



Vilazodone (Viibryd)) b



Other



20-40 c 



Quetiapine-XR (Seroquel)



AAP



150-300



Amitriptyline



TCA



100-250



Clomipramine



TCA



100-250



Desipramine



TCA



75-225



 Imipramine



TCA



100-250



 Nortiptyline



TCA



75-150


Third-line antidepressant d    
Phenelzine MAOI 30-75
Tranylcypromine MAOI 20-50

AAP = atypical antipsychotic.

  1. Second-line due to side-effect or safety profile, except where noted.
  2. Second-line due to lack of comparator and maintenance studies.
  3. Take with food.
  4. Use with caution due to dietary restrictions and drug–drug interactions.

Choosing an antidepressant


Usually there is not one definite choice of antidepressant for any given patient because there is so much individual variability in efficacy and side- effects. The choice is based primarily on individual profiles of efficacy, tolerability and anxiety indications. See Table 1 for guidance, and also consider these findings:

  • There is some evidence for slightly increased efficacy with escitalopram, mirtazapine, sertraline and venlafaxine, particularly in patients with more severe depression.
  • There is some evidence for better short-term tolerability with bupropi-  on, citalopram, desvenlafaxine, escitalopram and sertraline. Bupropion, desvenlafaxine, mirtazapine, vilazodone and vortioxetine have fewer sexual side-effects than other antidepressants.
  • A broad-spectrum medication (indicated for both depressive and anxiety disorders) is recommended due to high comorbidity of these disorders.
  • Efficacy for most anxiety disorders is demonstrated with escitalopram, paroxetine, sertraline and venlafaxine. Other antidepressants also may be effective for anxiety disorders, but they have not been studied.
  • Cognitive dysfunction is commonly seen in depression. There is some evidence that vortioxetine improves depression-associated cognitive dysfunction.

Antidepressant side-effects


Antidepressant side-effects vary by drug class and specific medication:

  • SSRIs can cause sexual dysfunction (most commonly decreased libido and delayed orgasm/ejaculation), insomnia, headaches, nausea and weight gain or loss. Some medications (fluvoxamine, paroxetine) may cause sedation.
  • SNRIs have a side-effect profile similar to that of SSRIs, but they can also cause hypertension, agitation, tremors and sweating.
  • Newer medications (desvenlafaxine, vilazodone, vortioxetine) and bupropion have fewer sexual side-effects than SSRIs and SNRIs.
  • Common adverse effects of MAOIs and TCAs include sedation, hypotension and anticholinergic effects (dry mouth, constipation, ocular side-effects, urinary hesitancy).
  • Uncommon but serious side-effects of SSRIs and SNRIs include hyponatremia and osteoporosis/fractures (most often seen with serotonergic medications), gastrointestinal bleeding (particularly when given with ASA or another NSAID) and QTc prolongation (primarily with TCAs and citalopram). TCAs and MAOIs may cause arrhythmias and postural hypotension, the latter being a risk factor for falls.

Antidepressants and suicide

Antidepressants have been associated with a small increased risk of suicidal thoughts, particularly in adolescents and young adults, and a decreased risk in older age groups. The relative risk may be elevated in some patient groups, but the absolute risk remains very small.

The risk of suicide is highest at the onset of treatment, when neurovegetative symptoms subside without the accompanying improvement in mood. Close monitoring is essential during the first few weeks of treatment. Given the consistent link between depression and suicidality, clinicians should screen for and treat depression attentively.

Maintenance Treatment

The goal for maintenance treatment of depression is preventing relapse and recurrence.

For uncomplicated episodes of depression, patients should continue on anti- depressants for at least four to six months after achieving symptom remission.

Patients with risk factors or complicated episodes (chronic, recurrent, severe, comorbid or difficult-to-treat depressive episodes) should continue on antidepressants for at least two years. Some patients will require lifetime treatment.

Stopping treatment

When stopping a patient’s medications, gradually taper the dose whenever possible (e.g., at least one week for each dose reduction). Caution patients about, and monitor for, discontinuation symptoms, which are  usually mild and transient. Use the mnemonic FINISH to identify discontinuation symptoms:

  • Flu-like symptoms
  • Insomnia
  • Nausea
  • Imbalance (dizziness)
  • Sensory disturbances (tingling, electric shocks)
  • Hyperarousal (agitation).

Discontinuation symptoms are more likely with paroxetine and venlafaxine (less so with their extended-release formulations), and less likely with fluoxetine.

No response to treatment

If the patient does not respond to treatment, consider these options:

  • Check the diagnosis (any bipolarity; missed comorbidity, such as substance use problems).
  • Optimize the antidepressant. Increase to the maximum tolerable dose within the dose range; ensure adherence for at least several weeks and manage side-effects.
  • Add psychotherapy.
  • Switch to another antidepressant. There is no difference whether switching within the same drug class (e.g., SSRI to another SSRI) or to a different class (e.g., SSRI to SNRI).
  • Add an augmenting agent. For example, add triiodothyronine (Cytomel; 25–50 mcg/day) or lithium (600–900 mg/day, or to therapeutic serum levels of 0.6–1.0 meq/L).
  • Alternatively, add an atypical antipsychotic (e.g., aripiprazole 2–10 mg/day; quetiapine-XR 150–300 mg/day; risperidone 0.5–3 mg/day; brexpiprazole 1–3 mg/day; note: olanzapine 2.5–10 mg/day is a second-line medication due to metabolic side-effects). Be careful about increased side-effect burden, especially with lithium and atypical antipsychotics.
  • Combine with another antidepressant in a different drug class. For example, add bupropion to an SSRI. Be careful about drug–drug interactions and increased side-effect burden.

Although there is little evidence to guide decisions when there is only partial response to treatment, most clinicians would augment or combine medications in order not to lose gains from the first antidepressant.

Switching between antidepressants

A washout period usually is not necessary when switching between  most antidepressants, except to and from MAOIs and RIMAs (reversible monoamine oxidase inhibitors). Generally, the second antidepressant can be started at a low dose while tapering off the first antidepressant (the X approach).

Be careful about increased side-effect burden when starting a medication before stopping another. In some patients, for example those who appear sensitive to side-effects, taper off the first antidepressant before starting the second (the V approach).

A useful online tool that guides switching patients from one antipsychotic or antidepressant to another is SwitchRx . It provides tapering and titration schedules, clinical tips and detailed information on drug pharmacokinetics and other precautions (see Resources).

Avoiding drug–drug interactions

Be aware of the effects that combining certain medications can have:

  • Fluoxetine and paroxetine can markedly inhibit cytochrome P450 (CYP) isoenzyme 2D6 and can increase blood levels of medications that are metabolized primarily by that isoenzyme (caution with TCAs, beta-blockers, codeine [reduces effect]).
  • Fluvoxamine can markedly inhibit CYP 1A2 and can increase blood levels of medications that are metabolized primarily by that isoenzyme (caution with statin drugs, warfarin, quinidine, phenytoin, cyclosporine, sildenafil, vardenafil, clozapine, buspirone, diazepam).
  • Duloxetine is extensively metabolized by CYP 1A2, so avoid using it with potent inhibitors of CYP 1A2 (such as fluvoxamine and quinolones).
  • Vortioxetine is metabolized by many isoenzymes, but primarily by CYP 2D6, so avoid using it with potent inhibitors of CYP 2D6 (e.g., fluxoxetine and paroxetine), and reduce the dose with moderate inhibitors of CYP 2D6 (e.g., bupropion, duloxetine, sertraline).
  • MAOIs (and moclobemide) should not be combined with other antidepressants or with serotonergic medications such as meperidine (Demerol) due to the risk of potentially fatal interactions.
  • Use caution with atypical antipsychotics because they have more interactions.

Drug interaction mobile apps, such as RxTx from the Canadian Pharmacists Association, or Epocrates and Medscape , are helpful, but they usually make very conservative recommendations.




In Depression

  • The Primary Care Practitioner Role
  • Screening & Assessment
  • Diagnosis
  • Treatment
    • Psychopharmacology
    • Psychotherapy
  • Clinical Tools
  • Resources & References

Treatment Overview
Psychotherapy

Follow us
  • Your Care
  • Health Info
  • Science and Research
  • Education
  • Professionals
  • Get Involved
  • Driving Change
  • About CAMH
  • Job Openings
  • Purchase Publications
  • Referral Form
  • For Reporters
  • Donor Services
  • Events

CAMH Switchboard

From the GTA: 416 535-8501


Toll-free: 1 800 463-2338

To Access CAMH Clinical Services

416 535-8501, press 2

We have multiple locations. Find directions.

Map of CAMH's Queen Street Site
  • Staff Tools

Copyright 2023 CAMH

  • Terms of Use
  • Accessibility
  • Site Map

Keep in touch with CAMH

Keep your finger on our pulse – latest CAMH news, discoveries and ways to get involved delivered to your inbox.

Please select a newsletter

Please complete the following:

    Required Fields

    Please select a newsletter option

    Please input a first name

    Please input a last name

    Please input an email address

    By clicking Sign Up below, I consent to receive electronic communications (as selected above) from CAMH and CAMH Foundation. To unsubscribe at any time click the link in our mailing or email: unsubscribe@camh.ca

    Please agree to the Terms of Use

     

    Thanks for Subscribing.

    We look forward to keeping you informed, inspired and involved in all things CAMH.

    Give for a world where mental health is health

    Your donation will fund the groundbreaking mental health research that is helping people on the path to recovery.

    $
    Other Ways to Give